Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury

A screen by Kost-Alimova et al.(1) suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Detalles Bibliográficos
Autores principales: Tabassum, Neha, Zhang, Hua, Stebbing, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670931/
https://www.ncbi.nlm.nih.gov/pubmed/33225317
http://dx.doi.org/10.1016/j.xcrm.2020.100145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670931/
https://www.ncbi.nlm.nih.gov/pubmed/33225317
http://dx.doi.org/10.1016/j.xcrm.2020.100145

Ejemplares similares